According to Zhitong Finance App News, Shiyao Group (01093.HK) issued an announcement stating that the Group and AstraZeneca signed an agreement in July 2026 to establish strategic research and development cooperation to develop novel small nucleic acid drug candidates using the Group's proprietary siRNA drug discovery platform and extracerpatic targeted delivery platform. The Board is pleased to announce that under the terms of the agreement, the Group has received an initial payment of $30 million from AstraZeneca on August 12, 2026. The receipt of this down payment marks the smooth progress of cooperation between the two parties, which is conducive to the Group's overall strategic layout and accelerates the development of small nucleic acid pipelines.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.